Nicholas P. Restifo

96.1k total citations · 36 hit papers
347 papers, 65.0k citations indexed

About

Nicholas P. Restifo is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Nicholas P. Restifo has authored 347 papers receiving a total of 65.0k indexed citations (citations by other indexed papers that have themselves been cited), including 306 papers in Immunology, 192 papers in Oncology and 94 papers in Molecular Biology. Recurrent topics in Nicholas P. Restifo's work include Immunotherapy and Immune Responses (239 papers), CAR-T cell therapy research (156 papers) and Immune Cell Function and Interaction (140 papers). Nicholas P. Restifo is often cited by papers focused on Immunotherapy and Immune Responses (239 papers), CAR-T cell therapy research (156 papers) and Immune Cell Function and Interaction (140 papers). Nicholas P. Restifo collaborates with scholars based in United States, Australia and Malaysia. Nicholas P. Restifo's co-authors include Steven A. Rosenberg, Luca Gattinoni, Mark E. Dudley, James C. Yang, Zhiya Yu, Christopher A. Klebanoff, Douglas C. Palmer, Richard M. Sherry, Pawel Muranski and James Chih‐Hsin Yang and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Nicholas P. Restifo

344 papers receiving 63.8k citations

Hit Papers

Cancer immunotherapy: mov... 1993 2026 2004 2015 2004 2002 2006 2015 2011 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer immunotherapy: moving beyond current vaccines
    2004 2.3k citations Steven A. Rosenberg, James C. Yang et al. profile →
  2. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
    2002 2.2k citations Mark E. Dudley, John R. Wunderlich et al. Science profile →
  3. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
    2006 2.0k citations Richard A. Morgan, Mark E. Dudley et al. Science profile →
  4. Adoptive cell transfer as personalized immunotherapy for human cancer
    2015 1.8k citations Steven A. Rosenberg, Nicholas P. Restifo Science profile →
  5. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
    2011 1.6k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. Clinical Cancer Research profile →
  6. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
    1998 1.5k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. profile →
  7. A human memory T cell subset with stem cell–like properties
    2011 1.4k citations Luca Gattinoni, Yun Ji et al. profile →
  8. Adoptive immunotherapy for cancer: harnessing the T cell response
    2012 1.3k citations Nicholas P. Restifo, Mark E. Dudley et al. profile →
  9. Adoptive cell transfer: a clinical path to effective cancer immunotherapy
    2008 1.2k citations Steven A. Rosenberg, Nicholas P. Restifo et al. profile →
  10. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    2003 1.2k citations Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences profile →
  11. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
    2008 1.0k citations Mark E. Dudley, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  12. Defining ‘T cell exhaustion’
    2019 953 citations Nicholas P. Restifo et al. profile →
  13. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells
    2005 812 citations Luca Gattinoni, Steven E. Finkelstein et al. The Journal of Experimental Medicine profile →
  14. Natural selection of tumor variants in the generation of “tumor escape” phenotypes
    2002 802 citations Nicholas P. Restifo et al. profile →
  15. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
    2010 791 citations James C. Yang, Mark E. Dudley et al. profile →
  16. Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
    2005 771 citations Giao Q. Phan, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  17. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
    2009 762 citations Luca Gattinoni, Douglas C. Palmer et al. profile →
  18. Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells
    2005 752 citations Christopher A. Klebanoff, Luca Gattinoni et al. Proceedings of the National Academy of Sciences profile →
  19. Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
    2003 751 citations Marc R. Theoret, Steven E. Finkelstein et al. The Journal of Experimental Medicine profile →
  20. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
    2013 718 citations Yun Ji, Zhiya Yu et al. profile →
  21. Adoptive immunotherapy for cancer: building on success
    2006 671 citations Luca Gattinoni, Steven A. Rosenberg et al. profile →
  22. Tumor-specific Th17-polarized cells eradicate large established melanoma
    2008 638 citations Pawel Muranski, Andrea Boni et al. Blood profile →
  23. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
    2010 635 citations Sergio A. Quezada, Tyler R. Simpson et al. The Journal of Experimental Medicine profile →
  24. Human memory T cells: generation, compartmentalization and homeostasis
    2013 628 citations Nicholas P. Restifo et al. profile →
  25. T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
    2009 618 citations Pawel Muranski, Nicholas P. Restifo et al. profile →
  26. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
    2005 592 citations Rong Zeng, Rosanne Spolski et al. The Journal of Experimental Medicine profile →
  27. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
    2014 585 citations Paul F. Robbins, Sadik H. Kassim et al. Clinical Cancer Research profile →
  28. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells
    2005 585 citations Paul A. Antony, Steven E. Finkelstein et al. The Journal of Immunology profile →
  29. Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma
    2002 565 citations Patrick Hwu, Nicholas P. Restifo et al. Journal of Clinical Oncology profile →
  30. Identification of human cancers deficient in antigen processing.
    1993 522 citations Nicholas P. Restifo, Steven A. Rosenberg et al. The Journal of Experimental Medicine profile →
  31. Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
    2010 518 citations Zhiya Yu, Marc R. Theoret et al. Cancer Research profile →
  32. Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
    2015 506 citations Sanja Stevanović, Lindsey M. Draper et al. Journal of Clinical Oncology profile →
  33. Ionic immune suppression within the tumour microenvironment limits T cell effector function
    2016 489 citations Christopher A. Klebanoff, Douglas C. Palmer et al. profile →
  34. T cell stemness and dysfunction in tumors are triggered by a common mechanism
    2019 409 citations Zhiya Yu, Douglas C. Palmer et al. Science profile →
  35. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
    2017 400 citations Nicholas P. Restifo et al. profile →
  36. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
    2019 301 citations Richard A. Morgan, James C. Yang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicholas P. Restifo United States 129 45.9k 39.1k 17.7k 9.7k 5.0k 347 65.0k
Carl H. June United States 139 40.7k 0.9× 52.4k 1.3× 24.4k 1.4× 16.4k 1.7× 14.0k 2.8× 657 85.8k
James P. Allison United States 125 50.0k 1.1× 39.1k 1.0× 13.1k 0.7× 5.1k 0.5× 2.4k 0.5× 487 72.3k
Mark J. Smyth Australia 143 52.9k 1.2× 37.6k 1.0× 20.2k 1.1× 3.7k 0.4× 3.3k 0.7× 595 81.6k
Drew M. Pardoll United States 132 46.7k 1.0× 45.0k 1.2× 23.5k 1.3× 6.0k 0.6× 3.7k 0.7× 403 83.2k
Suzanne L. Topalian United States 82 27.0k 0.6× 32.6k 0.8× 12.4k 0.7× 4.4k 0.4× 2.0k 0.4× 215 49.2k
Arlene H. Sharpe United States 130 47.7k 1.0× 28.8k 0.7× 16.3k 0.9× 5.8k 0.6× 1.1k 0.2× 408 75.8k
Laurence Zitvogel France 123 42.4k 0.9× 31.3k 0.8× 31.7k 1.8× 4.0k 0.4× 7.4k 1.5× 492 79.1k
Robert D. Schreiber United States 119 48.3k 1.1× 33.6k 0.9× 20.7k 1.2× 4.6k 0.5× 1.7k 0.3× 385 79.6k
Jedd D. Wolchok United States 119 29.7k 0.6× 45.3k 1.2× 16.2k 0.9× 2.8k 0.3× 3.7k 0.7× 568 65.0k
Gordon J. Freeman United States 141 54.1k 1.2× 38.6k 1.0× 14.7k 0.8× 4.1k 0.4× 1.9k 0.4× 419 82.7k

Countries citing papers authored by Nicholas P. Restifo

Since Specialization
Citations

This map shows the geographic impact of Nicholas P. Restifo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas P. Restifo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas P. Restifo more than expected).

Fields of papers citing papers by Nicholas P. Restifo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas P. Restifo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas P. Restifo. The network helps show where Nicholas P. Restifo may publish in the future.

Co-authorship network of co-authors of Nicholas P. Restifo

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas P. Restifo. A scholar is included among the top collaborators of Nicholas P. Restifo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas P. Restifo. Nicholas P. Restifo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Qiong J., et al.. (2016). Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunology Research. 4(3). 204–214. 175 indexed citations
2.
Slaney, Clare Y., Bianca von Scheidt, Alexander J. Davenport, et al.. (2016). Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research. 23(10). 2478–2490. 89 indexed citations
3.
Shi, Zhong, Zhiya Yu, Ivan Liadi, et al.. (2016). Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. The Journal of Immunology. 197(2). 644–654. 16 indexed citations
4.
Zhang, Ling, Richard A. Morgan, Joal D. Beane, et al.. (2015). Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research. 21(10). 2278–2288. 332 indexed citations
5.
Stevanović, Sanja, Lindsey M. Draper, Michelle M. Langhan, et al.. (2015). Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology. 33(14). 1543–1550. 506 indexed citations breakdown →
6.
Robbins, Paul F., Sadik H. Kassim, Thai L.N. Tran, et al.. (2014). A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research. 21(5). 1019–1027. 585 indexed citations breakdown →
7.
Chinnasamy, Dhanalakshmi, Eric Tran, Zhiya Yu, et al.. (2013). Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice. Cancer Research. 73(11). 3371–3380. 90 indexed citations
8.
Tran, Eric, Dhanalakshmi Chinnasamy, Zhiya Yu, et al.. (2013). Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. The Journal of Experimental Medicine. 210(6). 1125–1135. 349 indexed citations
9.
Chinnasamy, Dhanalakshmi, Zhiya Yu, Sid P. Kerkar, et al.. (2012). Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice. Clinical Cancer Research. 18(6). 1672–1683. 234 indexed citations
10.
Klebanoff, Christopher A., Luca Gattinoni, Douglas C. Palmer, et al.. (2011). Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. Clinical Cancer Research. 17(16). 5343–5352. 225 indexed citations
11.
Quezada, Sergio A., Tyler R. Simpson, Karl S. Peggs, et al.. (2010). Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. The Journal of Experimental Medicine. 207(3). 637–650. 635 indexed citations breakdown →
12.
Gattinoni, Luca, Yun Ji, & Nicholas P. Restifo. (2010). Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy. Clinical Cancer Research. 16(19). 4695–4701. 142 indexed citations
13.
Muranski, Pawel, Andrea Boni, Paul A. Antony, et al.. (2008). Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 112(2). 362–373. 638 indexed citations breakdown →
14.
Dudley, Mark E., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2008). Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology. 26(32). 5233–5239. 1017 indexed citations breakdown →
15.
Hinrichs, Christian S., Rosanne Spolski, Chrystal M. Paulos, et al.. (2008). IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 111(11). 5326–5333. 358 indexed citations
16.
Morgan, Richard A., Mark E. Dudley, John R. Wunderlich, et al.. (2006). Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science. 314(5796). 126–129. 1961 indexed citations breakdown →
17.
Zeng, Rong, Rosanne Spolski, Steven E. Finkelstein, et al.. (2005). Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. The Journal of Experimental Medicine. 201(1). 139–148. 592 indexed citations breakdown →
18.
Gattinoni, Luca, Steven E. Finkelstein, Christopher A. Klebanoff, et al.. (2005). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells. The Journal of Experimental Medicine. 202(7). 907–912. 812 indexed citations breakdown →
19.
Klebanoff, Christopher A., Steven E. Finkelstein, Deborah R. Surman, et al.. (2004). IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells. Proceedings of the National Academy of Sciences. 101(7). 1969–1974. 481 indexed citations
20.
Phan, Giao Q., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences. 100(14). 8372–8377. 1234 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carl H. June Breakdown of academic impact, for papers by James P. Allison Breakdown of academic impact, for papers by Mark J. Smyth Breakdown of academic impact, for papers by Drew M. Pardoll Breakdown of academic impact, for papers by Suzanne L. Topalian Breakdown of academic impact, for papers by Arlene H. Sharpe Breakdown of academic impact, for papers by Laurence Zitvogel Breakdown of academic impact, for papers by Robert D. Schreiber Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by Gordon J. Freeman
Rankless by CCL
2026